1. Home
  2. MIRM vs MGY Comparison

MIRM vs MGY Comparison

Compare MIRM & MGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • MGY
  • Stock Information
  • Founded
  • MIRM 2018
  • MGY 2017
  • Country
  • MIRM United States
  • MGY United States
  • Employees
  • MIRM N/A
  • MGY N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • MGY Oil & Gas Production
  • Sector
  • MIRM Health Care
  • MGY Energy
  • Exchange
  • MIRM Nasdaq
  • MGY Nasdaq
  • Market Cap
  • MIRM 3.8B
  • MGY 4.2B
  • IPO Year
  • MIRM 2019
  • MGY 2017
  • Fundamental
  • Price
  • MIRM $69.89
  • MGY $22.88
  • Analyst Decision
  • MIRM Strong Buy
  • MGY Hold
  • Analyst Count
  • MIRM 11
  • MGY 11
  • Target Price
  • MIRM $79.00
  • MGY $25.30
  • AVG Volume (30 Days)
  • MIRM 580.7K
  • MGY 2.0M
  • Earning Date
  • MIRM 11-04-2025
  • MGY 10-29-2025
  • Dividend Yield
  • MIRM N/A
  • MGY 2.61%
  • EPS Growth
  • MIRM N/A
  • MGY N/A
  • EPS
  • MIRM N/A
  • MGY 1.80
  • Revenue
  • MIRM $429,161,000.00
  • MGY $1,320,826,000.00
  • Revenue This Year
  • MIRM $53.14
  • MGY $0.69
  • Revenue Next Year
  • MIRM $19.83
  • MGY $4.00
  • P/E Ratio
  • MIRM N/A
  • MGY $12.78
  • Revenue Growth
  • MIRM 62.33
  • MGY 0.68
  • 52 Week Low
  • MIRM $36.88
  • MGY $19.09
  • 52 Week High
  • MIRM $78.55
  • MGY $29.02
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 43.37
  • MGY 44.34
  • Support Level
  • MIRM $68.34
  • MGY $22.68
  • Resistance Level
  • MIRM $71.86
  • MGY $23.75
  • Average True Range (ATR)
  • MIRM 2.36
  • MGY 0.55
  • MACD
  • MIRM -0.43
  • MGY 0.00
  • Stochastic Oscillator
  • MIRM 28.92
  • MGY 36.03

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About MGY Magnolia Oil & Gas Corporation

Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.

Share on Social Networks: